This topic contains a solution. Click here to go to the answer

Author Question: According to the SLII model, why is there a regression in commitment at development levels 2 and 3? ... (Read 269 times)

SO00

  • Hero Member
  • *****
  • Posts: 568
According to the SLII model, why is there a regression in commitment at development levels 2 and 3? Do you agree with this reasoning?
 
  What will be an ideal response?

Question 2

There is a lack of agreement among researchers on what specific characteristics define servant leadership.
 
  a. True
  b. False



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

welcom1000

  • Sr. Member
  • ****
  • Posts: 298
Answer to Question 1

Development levels are meant to be task-specific, not means of labeling employees. In the case of D2, employees may have started to learn a job but aren't quite as motivated as they were at the beginning. At the D3 level, employees are quite competent but have lost commitment to or enthusiasm for the project. What's not clear in the model is why subordinates who gain competence would lose enthusiasm or motivation. The argument is not supported (yet) with research.

Answer to Question 2

True





 

Did you know?

The National Institutes of Health have supported research into acupuncture. This has shown that acupuncture significantly reduced pain associated with osteoarthritis of the knee, when used as a complement to conventional therapies.

Did you know?

Throughout history, plants containing cardiac steroids have been used as heart drugs and as poisons (e.g., in arrows used in combat), emetics, and diuretics.

Did you know?

The average person is easily confused by the terms pharmaceutics and pharmacology, thinking they are one and the same. Whereas pharmaceutics is the science of preparing and dispensing drugs (otherwise known as the science of pharmacy), pharmacology is the study of medications.

Did you know?

For high blood pressure (hypertension), a new class of drug, called a vasopeptidase blocker (inhibitor), has been developed. It decreases blood pressure by simultaneously dilating the peripheral arteries and increasing the body's loss of salt.

Did you know?

The Food and Drug Administration has approved Risperdal, an adult antipsychotic drug, for the symptomatic treatment of irritability in children and adolescents with autism. The approval is the first for the use of a drug to treat behaviors associated with autism in children. These behaviors are included under the general heading of irritability and include aggression, deliberate self-injury, and temper tantrums.

For a complete list of videos, visit our video library